{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:42:23Z","timestamp":1790890943883,"version":"4.1.0"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Genetic autoinflammatory conditions constitute an increasing field. Among them, type I interferonopathies (IFNp-I) were conceptualized 15\u200a years ago as inborn errors of immunity due to chronic activation of the type I interferon (IFN-I) signalling pathway. Here, we provide recent insights in genetic mechanisms, clinical phenotypes and therapeutic options for these severe and rare disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>We will cover the novel findings into disease mechanisms, particularly the role of PTP1B in STING and IFNAR signalling, as well as the contribution of endosomal TLR pathways. We will also discuss the expanding phenotypic spectrum highlighted by recent case reports and cohort studies, together with the topic of clinical expressivity, including clinical non-penetrance, and possible mechanistic explanations such as monoallelic expression, the STING HAQ haplotype, and innovative approaches to characterise disease variability. Finally, we discuss current targeted therapeutic approaches for these disabling conditions, as well as potential new treatments for the future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Overall, these findings highlight the need to consider these rare diseases across a wide range of clinical phenotypes. Advances in next-generation sequencing have enabled a genetic diagnosis in suspected cases and the implementation of targeted treatments, thereby reducing diagnostic uncertainty and providing the possibility of genetic counselling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001179","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T08:00:08Z","timestamp":1784361608000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Type I interferonopathies: 15\u200ayears after the concept\u2014news and views"],"prefix":"10.1097","author":[{"given":"Samira","family":"Khaldi-Plassart","sequence":"first","affiliation":[{"name":"National Reference Centre for Inflammatory Rheumatism, Autoimmune Diseases and Systemic Interferonopathies in Children (RAISE), Hospices Civils de Lyon, Paediatric Nephrology, Rheumatology, Dermatology Unit, Woman-Mother and Children University Hospital, BRON Cedex, ERN RITA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Melki","sequence":"additional","affiliation":[{"name":"Department of General Paediatrics, Paediatric Rheumatology Unit, Armand-Trousseau Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Sorbonne Universit\u00e9, FHU INFLAMME"},{"name":"Universit\u00e9 Paris Cit\u00e9, Imagine Institute, Laboratory of Neurogenetics and Neuroinflammation, INSERM UMR 1163"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Fr\u00e9mond","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Imagine Institute, Laboratory of Neurogenetics and Neuroinflammation, INSERM UMR 1163"},{"name":"Paediatric Immuno-haematology and Rheumatology department, H\u00f4pital Necker-Enfants Malades, AP-HP. Centre Universit\u00e9 Paris Cit\u00e9, Reference Centre for Inflammatory Rheumatism, Autoimmune Diseases and Systemic Interferonopathies in Children (RAISE), F-CRIN CRI-IMIDIATE Network, ERN-RITA, FHU INFLAMME, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"R1-20260731","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","article-title":"Type I interferonopathies: a novel set of inborn errors of immunity","volume":"1238","author":"Crow","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"R2-20260731","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ana.410150109","article-title":"A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis","volume":"15","author":"Aicardi","year":"1984","journal-title":"Ann Neurol"},{"key":"R3-20260731","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10\u200ayears on","volume":"22","author":"Crow","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"R4-20260731","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41584-024-01184-8","article-title":"Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus","volume":"21","author":"Goldbach-Mansky","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"R5-20260731","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ard.2025.09.013","article-title":"Insights from a novel monogenic autoinflammatory disease: overview of a multicentric European cohort of 38 patients with COPA syndrome","volume":"85","author":"David","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"R6-20260731","doi-asserted-by":"crossref","first-page":"e20250235","DOI":"10.70962\/jhi.20250235","article-title":"Adult-onset STING-associated vasculopathy","volume":"2","author":"Riley","year":"2026","journal-title":"J Hum Immun"},{"key":"R7-20260731","doi-asserted-by":"crossref","first-page":"106044","DOI":"10.1016\/j.jbspin.2026.106044","article-title":"Adult-onset refractory inflammatory arthritis associated with somatic mosaicism of a truncating COPA mutation","volume":"93","author":"Avouac","year":"2026","journal-title":"Joint Bone Spine"},{"key":"R8-20260731","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1474-4422(24)00526-X","article-title":"Autoinflammatory encephalopathy due to PTPN1 haploinsufficiency: a case series","volume":"24","author":"Zhu","year":"2025","journal-title":"Lancet Neurol"},{"key":"R9-20260731","doi-asserted-by":"crossref","first-page":"e20250194","DOI":"10.70962\/jhi.20250194","article-title":"Identification of a novel TLR7 gain-of-function variant that underlies systemic lupus erythematosus","volume":"2","author":"Sethumadhavan","year":"2026","journal-title":"J Hum Immun"},{"key":"R10-20260731","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12026-025-09739-x","article-title":"A case of autoimmune hemolytic anemia with acquired functional mutation of the TLR7","volume":"74","author":"Han","year":"2026","journal-title":"Immunol Res"},{"key":"R11-20260731","doi-asserted-by":"crossref","first-page":"e20250266","DOI":"10.70962\/jhi.20250266","article-title":"TLR7 mutations leading to enhanced TLR7 signaling in humans","volume":"2","author":"Crow","year":"2026","journal-title":"J Hum Immun"},{"key":"R12-20260731","doi-asserted-by":"crossref","first-page":"e20250199","DOI":"10.70962\/jhi.20250199","article-title":"Novel TLR7 gain-of-function variant and review of the associated disease spectrum","volume":"2","author":"Tusseau","year":"2026","journal-title":"J Hum Immun"},{"key":"R13-20260731","doi-asserted-by":"crossref","first-page":"1671984","DOI":"10.3389\/fimmu.2025.1671984","article-title":"Case report: novel UNC93B1 variant causes rheumatoid arthritis and interstitial pneumonia","volume":"16","author":"He","year":"2025","journal-title":"Front Immunol"},{"key":"R14-20260731","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41590-024-01846-5","article-title":"Genetic variants in UNC93B1 predispose to childhood-onset systemic lupus erythematosus","volume":"25","author":"Al-Azab","year":"2024","journal-title":"Nat Immunol"},{"key":"R15-20260731","doi-asserted-by":"crossref","first-page":"e20250064","DOI":"10.70962\/jhi.20250064","article-title":"Incomplete penetrance in inborn errors of immunity: a skeleton in the closet-the sequel","volume":"1","author":"Bogunovic","year":"2025","journal-title":"J Hum Immun"},{"key":"R16-20260731","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41586-024-08346-4","article-title":"Monoallelic expression can govern penetrance of inborn errors of immunity","volume":"637","author":"Stewart","year":"2025","journal-title":"Nature"},{"key":"R17-20260731","doi-asserted-by":"crossref","first-page":"e20251470","DOI":"10.1084\/jem.20251470","article-title":"The STING HAQ haplotype and clinical nonpenetrance in COPA syndrome","volume":"223","author":"David","year":"2026","journal-title":"J Exp Med"},{"key":"R18-20260731","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","article-title":"TLR7 gain-of-function genetic variation causes human lupus","volume":"605","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"R19-20260731","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s10875-024-01660-6","article-title":"Interface gain-of-function mutations in TLR7 cause systemic and neuro-inflammatory disease","volume":"44","author":"David","year":"2024","journal-title":"J Clin Immunol"},{"key":"R20-20260731","doi-asserted-by":"crossref","first-page":"e179193","DOI":"10.1172\/JCI179193","article-title":"A de novo TLR7 gain-of-function mutation causing severe monogenic lupus in an infant","volume":"134","author":"Stremenova Spegarova","year":"2024","journal-title":"J Clin Invest"},{"key":"R21-20260731","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10875-024-01824-4","article-title":"Refractory autoimmune thrombocytopenia in an infant with a de novo TLR7 gain-of-function variant","volume":"45","author":"Menon","year":"2025","journal-title":"J Clin Immunol"},{"key":"R22-20260731","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ard.2025.01.011","article-title":"Somatic gain-of-function mutation in TLR7 causes early-onset systemic lupus erythematosus","volume":"84","author":"Zeng","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R23-20260731","doi-asserted-by":"crossref","first-page":"e20250196","DOI":"10.70962\/jhi.20250196","article-title":"TLR7 F507S gain-of-function mutation presenting with early-onset SLE and hypertriglyceridemia: response to JAK inhibition","volume":"2","author":"Parvaneh","year":"2026","journal-title":"J Hum Immun"},{"key":"R24-20260731","doi-asserted-by":"crossref","first-page":"e20232066","DOI":"10.1084\/jem.20232066","article-title":"Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus and chilblain lupus","volume":"221","author":"David","year":"2024","journal-title":"J Exp Med"},{"key":"R25-20260731","doi-asserted-by":"crossref","first-page":"e20232005","DOI":"10.1084\/jem.20232005","article-title":"Large-scale mutational analysis identifies UNC93B1 variants that drive TLR-mediated autoimmunity in mice and humans","volume":"221","author":"Rael","year":"2024","journal-title":"J Exp Med"},{"key":"R26-20260731","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/imcb.12807","article-title":"UNCovering new causes of monogenic systemic lupus erythematosus","volume":"102","author":"Ellyard","year":"2024","journal-title":"Immunol Cell Biol"},{"key":"R27-20260731","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11926-025-01207-7","article-title":"Juvenile-onset systemic lupus erythematosus: recent advances in pathogenesis and treatment","volume":"27","author":"Natoli","year":"2025","journal-title":"Curr Rheumatol Rep"},{"key":"R28-20260731","doi-asserted-by":"crossref","first-page":"eadi9575","DOI":"10.1126\/sciimmunol.adi9575","article-title":"Disrupted degradative sorting of TLR7 is associated with human lupus","volume":"9","author":"Mishra","year":"2024","journal-title":"Sci Immunol"},{"key":"R29-20260731","doi-asserted-by":"crossref","first-page":"eadi9769","DOI":"10.1126\/sciimmunol.adi9769","article-title":"UNC93B1 variants underlie TLR7-dependent autoimmunity","volume":"9","author":"Wolf","year":"2024","journal-title":"Sci Immunol"},{"key":"R30-20260731","article-title":"PTPN1-related autoinflammation is a common cause of Aicardi-Gouti\u00e8res Syndrome with reduced penetrance","author":"Calame","year":"2026","journal-title":"Neurology"},{"key":"R31-20260731","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.schres.2020.05.064","volume":"222","author":"Ayrolles","year":"2020","journal-title":"Schizophr Res"},{"key":"R32-20260731","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1055\/s-0040-1722673","article-title":"Hepatic involvement in Aicardi-Gouti\u00e8res syndrome","volume":"52","author":"Gavazzi","year":"2021","journal-title":"Neuropediatrics"},{"key":"R33-20260731","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10875-020-00832-4","article-title":"Persistent unexplained transaminitis in COPA syndrome","volume":"41","author":"Thaivalappil","year":"2021","journal-title":"J Clin Immunol"},{"key":"R34-20260731","doi-asserted-by":"crossref","first-page":"803.e11","DOI":"10.1016\/j.jaip.2020.11.007","article-title":"Overview of STING-associated vasculopathy with onset in infancy (SAVI) among 21 patients","volume":"9","author":"Fr\u00e9mond","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R35-20260731","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ymgme.2018.09.004","article-title":"Aicardi gouti\u00e8res syndrome is associated with pulmonary hypertension","volume":"125","author":"Adang","year":"2018","journal-title":"Mol Genet Metab"},{"key":"R36-20260731","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/humu.23975","article-title":"Genetic and phenotypic spectrum associated with IFIH1 gain-of-function","volume":"41","author":"Rice","year":"2020","journal-title":"Hum Mutat"},{"key":"R37-20260731","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ng.3279","article-title":"COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis","volume":"47","author":"Watkin","year":"2015","journal-title":"Nat Genet"},{"key":"R38-20260731","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10875-025-01883-1","article-title":"Mosaicism in two patients with COPA syndrome","volume":"45","author":"Tusseau","year":"2025","journal-title":"J Clin Immunol"},{"key":"R39-20260731","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1038\/s41467-026-69979-9","article-title":"Pharmacological stabilization of hypoxia-inducible factor 1-\u03b1 dampens the interferon response and promotes glycolysis in Aicardi-Gouti\u00e8res syndrome","volume":"17","author":"Batignes","year":"2026","journal-title":"Nat Commun"},{"key":"R40-20260731","doi-asserted-by":"crossref","first-page":"101333","DOI":"10.1016\/j.xcrm.2023.101333","article-title":"Single-cell RNA-sequencing of PBMCs from SAVI patients reveals disease-associated monocytes with elevated integrated stress response","volume":"4","author":"de Cevins","year":"2023","journal-title":"Cell Rep Med"},{"key":"R41-20260731","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3390\/cells14120939","article-title":"Muscle spatial transcriptomic reveals heterogeneous profiles in juvenile dermatomyositis and persistence of abnormal signature after remission","volume":"14","author":"Tragin","year":"2025","journal-title":"Cells"},{"key":"R42-20260731","doi-asserted-by":"crossref","first-page":"R102900","DOI":"10.7554\/eLife.102900.3","article-title":"Microglia replacement by ER-Hoxb8 conditionally immortalized macrophages provides insight into Aicardi\u2013Gouti\u00e8res syndrome neuropathology","volume":"14","author":"Nemec","year":"2026","journal-title":"eLife"},{"key":"R43-20260731","doi-asserted-by":"crossref","first-page":"e20242179","DOI":"10.1084\/jem.20242179","article-title":"The common HAQ STING allele prevents clinical penetrance of COPA syndrome","volume":"222","author":"Simchoni","year":"2025","journal-title":"J Exp Med"},{"key":"R44-20260731","doi-asserted-by":"crossref","first-page":"e20260007","DOI":"10.70962\/jhi.20260007","article-title":"Familial lupus associated with a P2RY8 variant: navigating the boundary between monogenic disease and genetic susceptibility to lupus","volume":"2","author":"David","year":"2026","journal-title":"J Hum Immun"},{"key":"R45-20260731","doi-asserted-by":"crossref","first-page":"e20211004","DOI":"10.1084\/jem.20211004","article-title":"P2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance","volume":"219","author":"He","year":"2022","journal-title":"J Exp Med"},{"key":"R46-20260731","doi-asserted-by":"crossref","first-page":"e20211972","DOI":"10.1084\/jem.20211972","article-title":"\u2018P2RY8-son\u2019 break of tolerance promotes SLE","volume":"219","author":"Tusseau","year":"2022","journal-title":"J Exp Med"},{"key":"R47-20260731","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/thoraxjnl-2019-213892","article-title":"Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage","volume":"75","author":"Fr\u00e9mond","year":"2020","journal-title":"Thorax"},{"issue":"(Suppl 1)","key":"R48-20260731","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.5152\/eurjrheum.2019.18177","article-title":"Baricitinib in therapy of COPA syndrome in a 15-year-old girl","volume":"7","author":"Krutzke","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"R49-20260731","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12969-019-0322-9","article-title":"Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome","volume":"17","author":"Boyadzhiev","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"R50-20260731","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12969-023-00817-8","article-title":"Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS\/CANDLE, SAVI, And AGS)","volume":"21","author":"Kanazawa","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"R51-20260731","doi-asserted-by":"crossref","first-page":"e27423","DOI":"10.1002\/ppul.27423","article-title":"Significant reduction of lung disease on baricitinib therapy in a patient with COPA syndrome","volume":"60","author":"Zuliani","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"R52-20260731","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10875-019-00645-0","article-title":"Efficacy and adverse events during janus kinase inhibitor treatment of SAVI syndrome","volume":"39","author":"Volpi","year":"2019","journal-title":"J Clin Immunol"},{"key":"R53-20260731","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/annrheumdis-2021-221814","article-title":"The 2021 European Alliance of Associations for Rheumatology\/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE\/PRAAS, SAVI and AGS","volume":"81","author":"Cetin Gedik","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R54-20260731","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ard.2025.01.016","article-title":"LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials","volume":"84","author":"Morand","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R55-20260731","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"R56-20260731","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/1744666X.2023.2268284","article-title":"Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus","volume":"20","author":"Gensous","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"R57-20260731","article-title":"Anifrolumab normalizes the type I interferon signature in a cohort of patients with type I interferonopathies [abstract]","volume":"75","author":"Alehashemi","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R58-20260731","doi-asserted-by":"crossref","first-page":"1374.e1","DOI":"10.1016\/j.jaip.2024.02.013","article-title":"Anifrolumab to treat a monogenic interferonopathy","volume":"12","author":"Doroudchi","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R59-20260731","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10875-024-01826-2","article-title":"Normalized interferon signatures and clinical improvements by IFNAR1 blocking antibody (anifrolumab) in patients with type i interferonopathies","volume":"45","author":"Kretzschmar","year":"2025","journal-title":"J Clin Immunol"},{"key":"R60-20260731","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/art.43145","article-title":"Sustained interferon signature suppression with anifrolumab in a patient with STING-associated vasculopathy with onset in infancy refractory to JAK inhibitor and dazukibart therapy","volume":"77","author":"Alehashemi","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R61-20260731","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ard.2025.10.021","article-title":"A de novo dominant-negative PSMB8 mutation causes severe CANDLE\/PRAAS due to arrested proteasome biogenesis","volume":"85","author":"Wolfgramm","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"R62-20260731","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jamadermatol.2024.2160","article-title":"Successful treatment of stimulator of interferon genes-associated vasculopathy of infantile onset SAVI syndrome with anifrolumab","volume":"160","author":"Mansilla-Polo","year":"2024","journal-title":"JAMA Dermatol"},{"key":"R63-20260731","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.70407","article-title":"Movement disorders in Aicardi\u2013Gouti\u00e8res syndrome and response to immunomodulation","author":"Gonzalez Saez-Diez","year":"2026","journal-title":"Ann Clin Transl Neurol"},{"key":"R64-20260731","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/dmcn.16199","article-title":"Reverse transcriptase inhibitors in Aicardi-Gouti\u00e8res syndrome: a crossover clinical trial","volume":"67","author":"Crow","year":"2025","journal-title":"Dev Med Child Neurol"},{"key":"R65-20260731","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1056\/NEJMc1810983","article-title":"Reverse-transcriptase inhibitors in the Aicardi\u2013Gouti\u00e8res syndrome","volume":"379","author":"Rice","year":"2018","journal-title":"N Engl J Med"},{"key":"R66-20260731","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1007\/s10875-021-01067-7","article-title":"Curative treatment of POMP-related autoinflammation and immune dysregulation (PRAID) by hematopoietic stem cell transplantation","volume":"41","author":"Meinhardt","year":"2021","journal-title":"J Clin Immunol"},{"key":"R67-20260731","doi-asserted-by":"crossref","first-page":"1120.e8","DOI":"10.1016\/j.jaci.2021.07.039","article-title":"Hematopoietic stem cell transplantation in a patient with proteasome-associated autoinflammatory syndrome (PRAAS)","volume":"149","author":"Verhoeven","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R68-20260731","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1182\/blood.2021011005","article-title":"HSCT corrects primary immunodeficiency and immune dysregulation in patients with POMP-related autoinflammatory disease","volume":"138","author":"Martinez","year":"2021","journal-title":"Blood"},{"key":"R69-20260731","doi-asserted-by":"crossref","first-page":"201699","DOI":"10.1016\/j.omta.2026.201699","article-title":"First successful allogeneic hematopoietic stem cell transplantation in STING-associated vasculopathy of infancy-a case report","volume":"34","author":"Yu","year":"2026","journal-title":"Mol Ther Adv"},{"key":"R70-20260731","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.1016\/S2665-9913(25)00337-6","article-title":"Efficacy and safety of enpatoran, a Toll-like receptor 7\/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"8","author":"Morand","year":"2026","journal-title":"Lancet Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:01:02Z","timestamp":1785495662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":70,"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001179","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}